fbpx
December 13, 2022

Chemotherapy Meets Its Match Against Aggressive ER+/HER2– BRCAs Chemotherapy Meets Its Match Against Aggressive ER+/HER2– BRCAs

SAN ANTONIO – Results of a study being hailed as practice changing showed that, for pre- or perimenopausal women with aggressive hormone receptor-positive, HER2-negative (HR+/HER2–) untreated breast […]
December 13, 2022

CTC-guided Therapy Beats Physician Choice in Met Breast Cancer CTC-guided Therapy Beats Physician Choice in Met Breast Cancer

SAN ANTONIO — When choosing between chemotherapy and endocrine therapy for patients with hormone receptor (HR)+/HER2- metastatic breast cancer, allowing the results from a blood test […]
December 13, 2022

Should You Quit Employment to Open a Practice? Should You Quit Employment to Open a Practice?

“Everyone says private practice is dying,” says Omar Maniya, MD, an emergency physician who left his hospital job for family practice in New Jersey. “But I […]
December 13, 2022

Cancer Patients Struggle to Access Psilocybin Before They Die Cancer Patients Struggle to Access Psilocybin Before They Die

In March 2020, when the world was struck by the news of the COVID-19 pandemic, Erinn Baldeschwiler received her own gut punch. She was diagnosed with […]
December 13, 2022

Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer

The investigational selective estrogen receptor degrader camizestrant was associated with significantly longer progression-free survival for women with advanced estrogen receptor–positive, HER2-negative (ER+/HER2–) breast cancers, compared with the […]
December 13, 2022

Steep Price for Surviving Childhood Lymphoma: Epigenetic Aging Steep Price for Surviving Childhood Lymphoma: Epigenetic Aging

NEW ORLEANS — Children with Hodgkin lymphoma can be cured with intensive chemotherapy, radiation, and other modalities, but a large majority of patients who survive into […]
December 13, 2022

High Response Rates With T-DXd in Early HER2-Low Breast Cancer High Response Rates With T-DXd in Early HER2-Low Breast Cancer

SAN Antonio – How do you shoot at an invisible target? It seems counterintuitive, but trastuzumab deruxtecan (T-DXd) (Enhertu), which combines an antibody targeted to HER2 with a […]
December 13, 2022

Three Antiseizure Medications Join List for Newborn Risks Three Antiseizure Medications Join List for Newborn Risks

A study of more than 4 million births over 20 years in five Scandinavian countries has reported that three antiseizure medications should be used with caution […]
December 13, 2022

Key Research on TNBC: Top 5 Picks From SABCS Key Research on TNBC: Top 5 Picks From SABCS

SAN ANTONIO — While major reports on hormone receptor (HR)–positive breast cancer took center stage at the San Antonio Breast Cancer Symposium (SABCS) 2022, research highlighting […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792793794795796797798799800801802803804
Next page
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0